Orchestra BioMed announces publication of AVIM data in JACC

Orchestra BioMed (OBIO) announced the publication of clinical data in JACC: Advances demonstrating that AVIM therapy significantly improved cardiac function in patients with hypertension and diastolic dysfunction, key contributors to the development of HFpEF. The publication, titled “Effects of AtrioVentricular Interval Modulation Therapy in Subjects with Hypertension and Diastolic Dysfunction,” reports findings from a retrospective treatment-blinded analysis of MODERATO II patients. The analysis demonstrated that AVIM therapy significantly reduced systolic blood pressure and improved echocardiographic markers of DD, a key contributor to HFpEF – a common comorbidity in patients with isolated systolic hypertension. Key findings: AVIM therapy significantly reduced both office and ambulatory SBP in patients with DD over 6 months, with office SBP reduced by 12.1+/-12.8 mmHg and ambulatory SBP by 8.3+/-9.7 mmHg. Patients treated with AVIM showed significant improvements in key measures of diastolic function, including increases in e and E/A ratio, consistent with improved myocardial relaxation and improved diastolic compliance.